Q-omics provides the consensus-scored MB21D2 profile across patient tissues and cancer cell-line models. MB21D2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MB21D2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MB21D2 RNA expression shows 19,205 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, HNSC, and ACC as cancer lineages where MB21D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MB21D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MB21D2 survival associations across molecular data types. MB21D2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MB21D2 RNA expression–survival associations across cancer types. High MB21D2 expression shows unfavorable associations in UCEC, ACC, COAD and HNSC, but favorable associations in KIRC and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MB21D2 RNA expression.
This table summarizes MB21D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MB21D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MB21D2 shows lower tumor expression in UCEC and LUAD and higher tumor expression in HNSC, KIRC, READ and THCA. The HNSC box plot shows higher MB21D2 RNA expression in tumor versus normal tissue (log2 FC = +1.683, t-test p < 0.001).
This table shows molecular features associated with MB21D2 in patient tissues and cancer cell lines. In patient samples, MB21D2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MB21D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
